Kiley Juergens Wealth Management LLC Sells 1,940 Shares of Johnson & Johnson (NYSE:JNJ)

Kiley Juergens Wealth Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 22,086 shares of the company’s stock after selling 1,940 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Kiley Juergens Wealth Management LLC’s holdings, making the stock its 20th largest holding. Kiley Juergens Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,462,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Tyche Wealth Partners LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $5,764,000. Avior Wealth Management LLC raised its holdings in Johnson & Johnson by 0.8% during the 4th quarter. Avior Wealth Management LLC now owns 37,366 shares of the company’s stock valued at $5,857,000 after buying an additional 309 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Johnson & Johnson by 21.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,109,544 shares of the company’s stock valued at $173,910,000 after buying an additional 196,065 shares during the period. Everence Capital Management Inc. raised its holdings in Johnson & Johnson by 8.9% during the 4th quarter. Everence Capital Management Inc. now owns 70,781 shares of the company’s stock valued at $11,094,000 after buying an additional 5,812 shares during the period. Finally, Wealth Alliance raised its holdings in Johnson & Johnson by 9.8% during the 4th quarter. Wealth Alliance now owns 12,887 shares of the company’s stock valued at $2,020,000 after buying an additional 1,152 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $149.12 on Tuesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The business’s fifty day simple moving average is $155.97 and its 200-day simple moving average is $155.57. The company has a market capitalization of $359.35 billion, a price-to-earnings ratio of 9.30, a PEG ratio of 2.44 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter last year, the company earned $2.68 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.33%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is presently 29.68%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Royal Bank of Canada decreased their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Morgan Stanley reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Raymond James increased their target price on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Bank of America reduced their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.